Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Targeting of functional antibody-CD59 fusion proteins to a cell surface
Hui-fen Zhang, … , Sherie L. Morrison, Stephen Tomlinson
Hui-fen Zhang, … , Sherie L. Morrison, Stephen Tomlinson
Published January 1, 1999
Citation Information: J Clin Invest. 1999;103(1):55-61. https://doi.org/10.1172/JCI4607.
View: Text | PDF
Research Article Article has an altmetric score of 9

Targeting of functional antibody-CD59 fusion proteins to a cell surface

  • Text
  • PDF
Abstract

Complement is involved in the pathogenesis of many diseases, and there is great interest in developing inhibitors of complement for therapeutic application. CD59 is a natural membrane-bound inhibitor of the cytolytic complement membrane attack complex (MAC). In this study, the preparation and characterization of antibody-CD59 (IgG-CD59) chimeric fusion proteins are described. Constructs were composed of soluble CD59 fused to an antibody-combining site at the end of CH1, after the hinge (H), and after CH3 Ig regions. The antigen specificity of each construct was for the hapten 5-dimethylamino-naphthalene-1-sulfonyl (dansyl). Correct folding of each IgG-CD59 fusion partner was indicated by recognition with anti-CD59 antibodies specific for conformational determinants and by IgG-CD59 binding to dansyl. The IgG-CD59 fusion proteins all bound specifically to dansyl-labeled Chinese hamster ovary cells and provided targeted cells, but not untargeted cells, with effective protection from complement-mediated lysis. Data indicate that CD59 must be positioned in close proximity to the site of MAC formation for effective function, and that modes of membrane attachment other than glycophosphatidylinositol linkage can affect CD59 functional activity.

Authors

Hui-fen Zhang, Jinghua Yu, Ednan Bajwa, Sherie L. Morrison, Stephen Tomlinson

×

Total citations by year

Year: 2018 2016 2015 2014 2012 2011 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1992 1981 Total
Citations: 1 1 1 1 3 2 2 2 2 2 3 1 4 4 1 3 1 1 1 36
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (36)

Title and authors Publication Year
Tissue-targeted complement therapeutics
S Tomlinson, JM Thurman
Molecular Immunology 2018
New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities
VM Holers, S Tomlinson, L Kulik, C Atkinson, B Rohrer, N Banda, JM Thurman
Seminars in Immunology 2016
An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice
MM Ruseva, V Ramaglia, BP Morgan, CL Harris
Proceedings of the National Academy of Sciences 2015
Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy
KM Marshall, S He, Z Zhong, C Atkinson, S Tomlinson
Journal of Experimental Medicine 2014
Complement Therapeutics
JD Lambris, VM Holers, D Ricklin
2012
Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: A possible option for treatment of myasthenia gravis
C Song, Z Xu, J Miao, J Xu, X Wu, F Zhang, H Lin, Z Li, HJ Kaminski
Muscle & Nerve 2012
Complement Therapeutics
JD Lambris, VM Holers, D Ricklin
2012
Soluble CD59 Expressed from an Adenovirus In Vivo Is a Potent Inhibitor of Complement Deposition on Murine Liver Vascular Endothelium
J Gandhi, SM Cashman, R Kumar-Singh, A Luttun
PloS one 2011
Immunopathogenesis of ischemia/reperfusion-associated tissue damage
A Ioannou, JD Lucca, GC Tsokos
Clinical Immunology 2011
Implication of complement system and its regulators in Alzheimer's disease
MV Kolev, MM Ruseva, CL Harris, BP Morgan, RM Donev
Current neuropharmacology 2009
Neuronal death in Alzheimer’s disease and therapeutic opportunities
R Donev, M Kolev, B Millet, J Thome
Journal of Cellular and Molecular Medicine 2009
Complement and Renal Transplantation: From Donor to Recipient
J Damman, TA Schuurs, RJ Ploeg, MA Seelen
Transplantation 2008
Anticomplement therapy
PA Kulkarni, V Afshar-Kharghan
Biologics : targets & therapy 2008
Complement in Lupus Nephritis: The Good, the Bad, and the Unknown
L Bao, RJ Quigg
Seminars in Nephrology 2007
Handbook of Systemic Autoimmune Diseases
M Karmegam, RJ Quigg
Handbook of Systemic Autoimmune Diseases 2007
Strategies of therapeutic complement inhibition
TE Mollnes, M Kirschfink
Molecular Immunology 2006
Membrane complement regulatory proteins
DD Kim, WC Song
Clinical Immunology 2006
Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9
C He, M Imai, H Song, RJ Quigg, S Tomlinson
Journal of immunology (Baltimore, Md. : 1950) 2005
Structural Biology of the Complement System
BP Morgan, S Tomlinson
Structural Biology of the Complement System 2005
Insights into the Human CD59 Complement Binding Interface Toward Engineering New Therapeutics
Y Huang, CA Smith, H Song, BP Morgan, R Abagyan, S Tomlinson
The Journal of biological chemistry 2005
Immunobiology of Organ Transplantation
DS Wilkes, WJ Burlingham
2004
Complement receptor 2 (CR2)-mediated targeting of complement inhibitors to sites of complement activation
Hongbin Song, Chun He, Christian Knaak, Joel M. Guthridge, V. Michael Holers and Stephen Tomlinson
Journal of Clinical Investigation 2003
Complement Regulatory Proteins: Are They Important in Disease?
M Nangaku
Journal of the American Society of Nephrology : JASN 2003
The complement system as a therapeutic target in autoimmunity
VM Holers
Clinical Immunology 2003
Generation of a Recombinant, Membrane-targeted Form of the Complement Regulator CD59: ACTIVITY IN VITRO AND IN VIVO
DA Fraser, CL Harris, AS Williams, M Mizuno, S Gallagher, RA Smith, BP Morgan
The Journal of biological chemistry 2003
Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo
CL Harris, AS Williams, SM Linton, BP Morgan
Clinical & Experimental Immunology 2002
Expression of complement regulating factors in gastric cancer cells
T Inoue, M Yamakawa, T Takahashi
Molecular pathology : MP 2002
Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeutic
DA Fraser, CL Harris, RA Smith, BP Morgan
Protein science : a publication of the Protein Society 2002
Antibody-mediated activation of the classical complement pathway in xenograft rejection
A Roos, MR Daha
Transplant Immunology 2002
Targeting of Functional Antibody-Decay-accelerating Factor Fusion Proteins to a Cell Surface
H Zhang, S Lu, SL Morrison, S Tomlinson
The Journal of biological chemistry 2001
Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins in Pichia pastoris
RJ Quigg, C He, BK Hack, JJ Alexander, BP Morgan
Immunology 2000
PNH and the GPI-Linked Proteins
CJ Parker
PNH and the GPI-Linked Proteins 2000
Xenotransplantation
B Soin, CM Vial, PJ Friend
The British journal of surgery 2000
Strategies for targeting complement inhibitors in ischaemia/reperfusion injury
J Dong, JR Pratt, RA Smith, I Dodd, SH Sacks
Molecular Immunology 1999
The Complement System
A Agostoni, M Cicardi, M Gardinali, L Bergamaschini
International journal of immunopathology and pharmacology 1992
Autoimmunity
AJ King, SA Schwartz, DE Lopatin, JJ Voorhees, LA Diaz
International Journal of Dermatology 1981

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 27 patents
14 readers on Mendeley
See more details